Developer docs
API playgroundTry for free, no card

Search company profiles

AvantGuard

Full company profile

uuid0002oe2

Namestring
AvantGuard
Legal namestring
AvantGuard, Inc.
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIthaca, United States
HQ citystring
Ithaca
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial coatings, surface disinfection products, wound care formulations, medical device antimicrobials, infection control solutions
Industry5 codes
PRIMARYIMAEABAH
Industrial Biocides & Preservatives
SECONDARYCRABAEAH
Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic)
Consumer Products & Retail/Beauty & Personal Care/Bath, Body & Personal Cleansing
SECONDARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYCRAJANAB
Concentrated Surface Disinfectants (Dilutable Liquids)
SECONDARYCRADANAI
Hand Sanitizers & Antibacterial Personal Care
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Consumer Fragrances & Personal Care Manufacturing (Non-cosmetic)
NAICS code2 codes
  • Soap and Cleaning Compound Manufacturing32561
  • Surface Active Agent Manufacturing325613
SIC code2 codes
  • Miscellaneous Chemical Products2890
  • Industrial Organic Chemicals2860
Product category
Antimicrobial disinfectants and infection control
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Antimicrobial Products
TypeHardware Sales
Description

Sale of formulated products including AvantSept (antiseptic wash), AvantGel (topical hydrogel), and Avant24 (residual surface disinfectant). Products target healthcare facilities, medical device manufacturers, wound care, and consumer skincare applications.

avantguardinc.com
2Licensing and Technology Partnerships
TypeLicensing Royalties
Description

The company positions its technology as a platform applicable across multiple markets including surface disinfection, dermatology, wound care, and medical devices. Licensing of the Avantamine chemistry to larger healthcare and consumer product companies represents a potential revenue stream.

avantguardinc.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Avantamine
Description

Proprietary stabilized chloramine molecule inspired by the body's natural immune defenses, providing broad-spectrum antimicrobial activity without resistance generation or safety issues like skin irritation or surface corrosion.

avantguardinc.com
+4 more records
Core offering1 text field

AvantGuard develops and sells formulated antimicrobial products based on its proprietary Avantamine™ chloramine chemistry. The company offers Polyvantoin Chlorine (residual surface disinfectant), AvantSept (antimicrobial wash), AvantGel (wound care hydrogel), and Avant24 (24-hour surface protection) for healthcare facilities, medical device manufacturers, wound care providers, and dermatology applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 100,000x more effective than chlorhexidine against bacterial biofilms
+5 more records
Product overview1 text field

AvantGuard is a biotechnology company developing a platform technology based on its proprietary Avantamine™ molecule - a stabilized chloramine inspired by the human immune system's natural pathogen-fighting chemistry. The core product portfolio includes polyvantoin chlorine (the primary disinfectant formulation combining Avantamine with hydrophilic monomers for stability), available in multiple delivery formats: AvantSept (antimicrobial wash), AvantGel (hydrogel for wound care), and Avant24 (residual surface disinfectant providing 24-hour protection). The platform addresses critical healthcare challenges including Candida auris infections, healthcare-associated infections, dermatophytosis, and diabetic foot ulcer infections, targeting a combined market opportunity exceeding $30 billion across surface disinfection, dermatology, and wound care segments.

Product and service4 records
1Polyvantoin Chlorine
CategoryAntimicrobial disinfectant
Description

A polymer-based disinfectant combining Avantamine™ chloramine monomer with hydrophilic monomers to stabilize chlorine in solution. It provides broad-spectrum antimicrobial activity against ESKAPE pathogens, C. auris, and biofilms, with residual surface protection lasting weeks. Targeted at healthcare facilities and infection control applications.

2AvantSept
CategoryAntimicrobial wash
Description

An antimicrobial wash formulation for skin decontamination, wound care, and infection control. Part of AvantGuard's wound care portfolio targeting chronic wounds and diabetic foot ulcers with broad-spectrum efficacy against drug-resistant pathogens and biofilm-forming organisms.

3AvantGel
CategoryWound care hydrogel
Description

A polyvantoin chlorine hydrogel formulation for wound care and topical antimicrobial treatment of diabetic foot ulcers and skin infections. Provides sustained antifungal and antibacterial activity with demonstrated superiority over standard treatments like silver sulfadiazine and clotrimazole in biofilm eradication models.

4Avant24
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Carine Nkemngong from AvantGuard co-authored a scientific paper with Peter Teska from Diversey on biofilm research and pathogen persistence in healthcare and food processing environments.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Dr. Stephen Davis at University of Miami for definitive animal model testing of AvantGel and AvantSept against Pseudomonas aeruginosa and Staphylococcus aureus in an in vivo biofilm eradication porcine model.

3NIAID Pre-Clinical Services / Element Materials Technology
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH-funded contract testing of polyvantoin chlorine against ESKAPE pathogens at Element Materials Technology under NIAID Pre-Clinical Services program.

avantguardinc.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ithaca-based research partner conducting C. auris clade testing (I, II, III, IV) to demonstrate consistent MIC values across different geographic strains.

5Fungus Testing Laboratory at UT Health Science Center San Antonio
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CLSI-compliant antifungal susceptibility testing (M27 and M38 methodologies) against multiple Candida species and pathogenic fungi.

avantguardinc.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Halomine Inc.
TypeDirect peer
Description

AvantGuard's parent company; both are founded on the Avantamine chloramine technology platform and target antimicrobial applications in healthcare, food safety, and industrial markets. Most direct technology peer.

TypeDirect peer
Description

FDA-approved developer of Brexafemme (ibrexafungerp), the first new antifungal class in decades, with active programs targeting Candida auris. Direct peer in antifungal innovation for drug-resistant fungal pathogens.

TypeDirect peer
Description

Developer of Rezzayo (rezafungin), FDA-approved in 2023 for candidemia and invasive candidiasis, with ongoing C. auris development. Direct peer in echinocandin-class antifungals for resistant fungal infections.

TypeEmerging player
Description

Late-stage clinical biotech developing olorofim, a novel oral antifungal for invasive aspergillosis and rare mold infections including C. auris. Emerging peer in antifungal resistance space with similar unmet-need focus.

TypeBroad incumbent
Description

$70B+ market cap global leader in water, hygiene, and infection prevention with deep hospital and long-term care sales channels. Broad incumbent in surface disinfection where AvantGuard's Avant24 would compete.

TypeBroad incumbent
Description

Global hygiene and cleaning solutions company (acquired by Solenis); existing AvantGuard research co-author partner (Peter Teska). Broad incumbent in healthcare surface disinfection and a potential licensing partner or competitor.

TypeBroad incumbent
Description

Global leader in wound care and surgical solutions, including Mepilex antimicrobial dressings. Broad incumbent in advanced wound care where AvantGuard's AvantGel targets diabetic foot ulcers.

TypeBroad incumbent
Description

Public medical device company with leading wound therapeutics portfolio (Avelle, AQUACEL) including antimicrobial silver dressings. Broad incumbent in advanced wound care segment.

TypeBroad incumbent
Description

Inventor of PURELL and dominant player in hand hygiene and skin antiseptic products for healthcare and consumer markets. Broad incumbent in antiseptic wash category where AvantGuard's AvantSept competes.

TypeEmerging player
Description

Clinical-stage biopharma developing inhaled anti-infectives for respiratory fungal infections. Emerging peer in anti-infective innovation with similar small-cap R&D profile, though different delivery modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds23 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AvantGuard

Antimicrobial disinfectants and infection controlavantguardinc.com

AvantGuard firmographics

Firmographics
Name
AvantGuard
Legal name
AvantGuard, Inc.
Website
https://avantguardinc.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

AvantGuard industry classification

Industry
Product category
Antimicrobial disinfectants and infection control
NAICS
Soap and Cleaning Compound Manufacturing (32561), Surface Active Agent Manufacturing (325613)
SIC
Miscellaneous Chemical Products (2890), Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYIMAEABAH
Industrial Biocides & Preservatives
SECONDARYCRABAEAH
Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic)
Consumer Products & Retail/Beauty & Personal Care/Bath, Body & Personal Cleansing
SECONDARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYCRAJANAB
Concentrated Surface Disinfectants (Dilutable Liquids)
SECONDARYCRADANAI
Hand Sanitizers & Antibacterial Personal Care
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Consumer Fragrances & Personal Care Manufacturing (Non-cosmetic)

Keywords

  • Antimicrobial coatings
  • Surface disinfection products
  • Wound care formulations
  • Medical device antimicrobials
  • Infection control solutions

Where AvantGuard is headquartered

Location

Headquarters

HQ city
Ithaca
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AvantGuard business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Antimicrobial Products: Sale of formulated products including AvantSept (antiseptic wash), AvantGel (topical hydrogel), and Avant24 (residual surface disinfectant). Products target healthcare facilities, medical device manufacturers, wound care, and consumer skincare applications.
  2. Licensing and Technology Partnerships: The company positions its technology as a platform applicable across multiple markets including surface disinfection, dermatology, wound care, and medical devices. Licensing of the Avantamine chemistry to larger healthcare and consumer product companies represents a potential revenue stream.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

AvantGuard product offering

Product offering

Core offering

AvantGuard develops and sells formulated antimicrobial products based on its proprietary Avantamine™ chloramine chemistry. The company offers Polyvantoin Chlorine (residual surface disinfectant), AvantSept (antimicrobial wash), AvantGel (wound care hydrogel), and Avant24 (24-hour surface protection) for healthcare facilities, medical device manufacturers, wound care providers, and dermatology applications.

Product overview

AvantGuard is a biotechnology company developing a platform technology based on its proprietary Avantamine™ molecule - a stabilized chloramine inspired by the human immune system's natural pathogen-fighting chemistry. The core product portfolio includes polyvantoin chlorine (the primary disinfectant formulation combining Avantamine with hydrophilic monomers for stability), available in multiple delivery formats: AvantSept (antimicrobial wash), AvantGel (hydrogel for wound care), and Avant24 (residual surface disinfectant providing 24-hour protection). The platform addresses critical healthcare challenges including Candida auris infections, healthcare-associated infections, dermatophytosis, and diabetic foot ulcer infections, targeting a combined market opportunity exceeding $30 billion across surface disinfection, dermatology, and wound care segments.

Differentiator

Problem solved

Functional benefit

Brands

  • Avantamine: Proprietary stabilized chloramine molecule inspired by the body's natural immune defenses, providing broad-spectrum antimicrobial activity without resistance generation or safety issues like skin irritation or surface corrosion.
  • AvantSept
  • AvantGel
  • Avant24
  • Polyvantoin chlorine

Products and services

  • Polyvantoin Chlorine A polymer-based disinfectant combining Avantamine™ chloramine monomer with hydrophilic monomers to stabilize chlorine in solution. It provides broad-spectrum antimicrobial activity against ESKAPE pathogens, C. auris, and biofilms, with residual surface protection lasting weeks. Targeted at healthcare facilities and infection control applications.
  • AvantSept An antimicrobial wash formulation for skin decontamination, wound care, and infection control. Part of AvantGuard's wound care portfolio targeting chronic wounds and diabetic foot ulcers with broad-spectrum efficacy against drug-resistant pathogens and biofilm-forming organisms.
  • AvantGel A polyvantoin chlorine hydrogel formulation for wound care and topical antimicrobial treatment of diabetic foot ulcers and skin infections. Provides sustained antifungal and antibacterial activity with demonstrated superiority over standard treatments like silver sulfadiazine and clotrimazole in biofilm eradication models.
  • Avant24

Quantifiable outcome

  • 100,000x more effective than chlorhexidine against bacterial biofilms
  • +5 more outcomes

Companies that use AvantGuard

Customer profile

Segments5 records

Ideal customer profiles4 records

AvantGuard technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AvantGuard partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • DiverseyminorStrategic or Co-development PartnerDr. Carine Nkemngong from AvantGuard co-authored a scientific paper with Peter Teska from Diversey on biofilm research and pathogen persistence in healthcare and food processing environments.
  • University of MiamicoreStrategic or Co-development PartnerResearch collaboration with Dr. Stephen Davis at University of Miami for definitive animal model testing of AvantGel and AvantSept against Pseudomonas aeruginosa and Staphylococcus aureus in an in vivo biofilm eradication porcine model.
  • NIAID Pre-Clinical Services / Element Materials TechnologycoreStrategic or Co-development PartnerNIH-funded contract testing of polyvantoin chlorine against ESKAPE pathogens at Element Materials Technology under NIAID Pre-Clinical Services program.
  • iFybercoreStrategic or Co-development PartnerIthaca-based research partner conducting C. auris clade testing (I, II, III, IV) to demonstrate consistent MIC values across different geographic strains.
  • Fungus Testing Laboratory at UT Health Science Center San AntoniocoreStrategic or Co-development PartnerCLSI-compliant antifungal susceptibility testing (M27 and M38 methodologies) against multiple Candida species and pathogenic fungi.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

AvantGuard competitors and assessment

Company assessment

Direct peers

  • Halomine Inc. AvantGuard's parent company; both are founded on the Avantamine chloramine technology platform and target antimicrobial applications in healthcare, food safety, and industrial markets. Most direct technology peer.
  • Scynexis: FDA-approved developer of Brexafemme (ibrexafungerp), the first new antifungal class in decades, with active programs targeting Candida auris. Direct peer in antifungal innovation for drug-resistant fungal pathogens.
  • Cidara Therapeutics: Developer of Rezzayo (rezafungin), FDA-approved in 2023 for candidemia and invasive candidiasis, with ongoing C. auris development. Direct peer in echinocandin-class antifungals for resistant fungal infections.

Emerging players

  • F2G (F2G Biotech): Late-stage clinical biotech developing olorofim, a novel oral antifungal for invasive aspergillosis and rare mold infections including C. auris. Emerging peer in antifungal resistance space with similar unmet-need focus.
  • Pulmatrix: Clinical-stage biopharma developing inhaled anti-infectives for respiratory fungal infections. Emerging peer in anti-infective innovation with similar small-cap R&D profile, though different delivery modality.

Broad incumbents

  • Ecolab: $70B+ market cap global leader in water, hygiene, and infection prevention with deep hospital and long-term care sales channels. Broad incumbent in surface disinfection where AvantGuard's Avant24 would compete.
  • Diversey: Global hygiene and cleaning solutions company (acquired by Solenis); existing AvantGuard research co-author partner (Peter Teska). Broad incumbent in healthcare surface disinfection and a potential licensing partner or competitor.
  • Mölnlycke Health Care: Global leader in wound care and surgical solutions, including Mepilex antimicrobial dressings. Broad incumbent in advanced wound care where AvantGuard's AvantGel targets diabetic foot ulcers.
  • ConvaTec: Public medical device company with leading wound therapeutics portfolio (Avelle, AQUACEL) including antimicrobial silver dressings. Broad incumbent in advanced wound care segment.
  • GOJO Industries (Purell): Inventor of PURELL and dominant player in hand hygiene and skin antiseptic products for healthcare and consumer markets. Broad incumbent in antiseptic wash category where AvantGuard's AvantSept competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AvantGuard social profiles

Digital presence

AvantGuard financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AvantGuard leadership team

Management profile

Number of profiles

Profiles4 records

AvantGuard funding detail

Funding detail

Funding overview

Funding rounds23 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AvantGuard M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AvantGuard

What does AvantGuard do?

AvantGuard develops and sells formulated antimicrobial products based on its proprietary Avantamine™ chloramine chemistry. The company offers Polyvantoin Chlorine (residual surface disinfectant), AvantSept (antimicrobial wash), AvantGel (wound care hydrogel), and Avant24 (24-hour surface protection) for healthcare facilities, medical device manufacturers, wound care providers, and dermatology applications.

Is AvantGuard a public or private company?

AvantGuard is a private company. It is classified as venture growth investor backed and is currently operating.

When was AvantGuard founded?

AvantGuard was founded in 2018. It employs 11 to 50 people.

Where is AvantGuard based?

AvantGuard is headquartered in Ithaca, United States, in the North America region.

How does AvantGuard make money?

Two revenue lines are on record. Antimicrobial Products are the primary driver. The others are licensing and Technology Partnerships.

Who are AvantGuard's main competitors?

Direct peers on record are Halomine Inc., Scynexis and Cidara Therapeutics. Emerging players are F2G (F2G Biotech) and Pulmatrix. Broad incumbents are Ecolab, Diversey, Mölnlycke Health Care, ConvaTec and GOJO Industries (Purell).

Does AvantGuard have an API?

No public API is recorded for AvantGuard.

What industry is AvantGuard in?

AvantGuard's product category is Antimicrobial disinfectants and infection control. Its primary akta.pro industry code is IMAEABAH, Industrial Biocides & Preservatives, with a secondary code of CRABAEAH, Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic). Its NAICS code is 32561 and its SIC code is 2890.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0AvantGuard: $2.65 Million In NIH Grants Closed To Advance Next Generation Antimicrobial TechnologiesAvantGuard, an Ithaca-based biotechnology company, has been awarded three NIH grants totaling $2.65 million to advance its proprietary Avantamine antimicrobial technology platform across surface disinfection, dermatology, and chronic wound care applications. The grants include a $2 million Phase IIB award for long-lasting antimicrobial surface disinfectants, a $300,000 Phase I grant for dermatophytosis therapies, and a $350,000 Phase I grant targeting infections in chronic diabetic foot ulcers. The funding will support preclinical development, formulation optimization, and regulatory planning as the company progresses its product candidates—AvantSept, AvantGel, and Avant24—toward clinical readiness.BioSpaceAvantGuard Awarded $2.65 Million in NIH Grants to Advance Next-Generation Antimicrobial TechnologiesAvantGuard, Inc. announced receipt of three NIH research grants totaling $2.65 million, including a $2 million Phase IIB grant for surface disinfection, a $300,000 Phase I grant for dermatophytosis treatments, and a $350,000 Phase I grant for chronic diabetic foot ulcer infections. The funding will support preclinical development, formulation optimization, and regulatory planning for the company's proprietary Avantamine™ molecule technology, which aims to deliver broad-spectrum antimicrobial activity without resistance generation. The grants validate AvantGuard's approach to addressing antibiotic resistance and lay groundwork for future clinical trials across multiple applications in infection prevention and wound management.TechCrunchAvantGuard wants to turn chlorine into the best antiseptic you’ve ever seenAvantGuard, spun from Cornell, is developing a polymer-based N-halamine coating that binds chlorine to surfaces for antimicrobial protection. Its product 247 claims 99.9% pathogen reduction within two hours and has passed EPA testing. The company predicts over $70 billion in market impact and expects regulatory approval in early 2024.Silicon Valley JournalsAvantGuard Raised $2.85M to Accelerate Research and DevelopmentAntimicrobial company AvantGuard has closed a $2.85 million seed funding round led by Blue Ledge Capital, with participation from SOSV, LaunchNY, and Red Bear Angels. The capital will be used to accelerate research and development of its antimicrobial chemistries, hire additional scientists, and expand the company's global presence.FinSMEsAvantGuard Raises $2.85M in Seed FundingAvantGuard, a New York-based chemistry company, raised $2.85M in seed funding from Blue Ledge Capital, SOSV, LaunchNY, and Red Bear Angels. The funds will accelerate development of its antimicrobial chemistries and hire additional scientists. The company aims to expand its global reach with products that provide long-term protection against pathogens.PR NewswireAvantGuard Secures $2.85 Million in Oversubscribed Seed Round Funding to Accelerate Research and DevelopmentAvantGuard secured $2.85 million in an oversubscribed seed funding round led by Blue Ledge Capital, with participation from SOSV, LaunchNY, and Red Bear Angels. The company intends to utilize these funds alongside over $7.5 million in existing grants to accelerate research and development of its antimicrobial chemistries and hire additional scientists. This investment supports AvantGuard's goal of expanding its global reach and commercializing solutions for pathogen protection in sectors such as healthcare and food production.AvantguardincAvantGuard Secures $2.85 Million in Oversubscribed Seed Round Funding to Accelerate Research and DevAvantGuard announced the successful completion of a $2.85 million oversubscribed seed funding round to accelerate the development of its antimicrobial chemistries and expand its global reach. The investment includes contributions from Blue Ledge Capital, SOSV, LaunchNY, and Red Bear Angels, which will be combined with over $7.5 million in grants to hire additional scientists and scale operations.Venture Capital Access OnlineAvantGuard Secures $2.85 Million in Oversubscribed Seed Round Funding to Accelerate Research and DevelopmentAvantGuard, a company in the antimicrobial industry, has successfully raised $2.85 million in an oversubscribed seed funding round to enhance its research and development. The funding will facilitate the advancement of its innovative antimicrobial chemistries and enable the hiring of additional scientists. With this investment, AvantGuard plans to expand its global reach and improve its product offerings in the field of pathogen-fighting solutions.VC News DailyAvantGuard Closes $2.85M Seed RoundAvantGuard, a chemistry-based technology company specializing in antimicrobial solutions, announced the successful completion of its seed funding round, raising $2.85 million from a consortium of investors. The investors include new investor Blue Ledge Capital and follow-on investors SOSV, LaunchNY, and Red Bear Angels. The funds will be used to accelerate development of the company's antimicrobial chemistries, hire additional scientists, and expand its global reach.